An Emerging Markets News Commentary
ORLANDO, Fla., July 16, 2020 (GLOBE NEWSWIRE) -- Remote medical biometric technology company Biotricity (OTCQB: BTCY) dropped year-end guidance on Wednesday, addressing its challenges and identifying positive events.
The milestones for fiscal 2020 are significant.
They are as follows:
- Increased Market Penetration: Biotricity expanded its customer base and its geographic footprint quarter over quarter by expanding into 6 more states.
Our take: This helps support the narrative that remote medicine, televisits, etc. are the way of the future, and more importantly, that Biotricity is expanding its acceptance in the field. - Increases in its Core Service Revenues: Technology fee revenues have consistently increased over the course of our fiscal year ended March 31, 2020, creating a strong repeatable and growing revenue trajectory.
Our take: Strong revenues often validate the core service offering, operational efficiency and may help ward off toxic financing. - Continuous Innovation: The Company has filed for a 510(k) FDA clearance of its next generation software platform, designed to drive operational efficiency and improve monitoring effectiveness for its clinicians.
Our take: An important moment coming for the Company.
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php.
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
EMC has been paid $157,500 and 75,000 restricted shares for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php
Emerging Markets Consulting, LLC
Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711
E-mail: Web: www.emergingmarketsllc.com